Abstract
Fluorescence resonance energy transfer substrates were designed and tested as substrates for ADAM9. The donor/quencher pair used were 5-carboxyfluorescein (Fam) and 4-(4-dimethyl-aminophenylazo)benzoyl (Dabcyl) since they have been well studied sensitive fluorescent probes. The peptides based on precursor TNF-alpha, Dabcyl-Ser-Pro- Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser-Lys(Fam)-NH2 and Dabcyl-Leu-Ala-Gln-Ala-HomoPhe-Arg-Ser-Lys(Fam)-NH2, and C-terminal TGF-alpha, Dabcyl-Glu-His-Ala-Asp-Leu-Leu-Ala-Val-Val-Ala-Ala-Lys(Fam)-NH2 cleavage sites were effectively processed by ADAM9 with turnover numbers of 100 ± 20 x 10-2 min-1, 20 ± 10 x 10-2 min-1, and 10 ± 3 x 10-2 min-1. In addition, a peptide based on the 33kDa cleavage site of the low affinity receptor for IgE, CD23, Dabcyl-Leu- Arg-Ala-Glu-Gln-Gln-Arg-Leu-Lys-Ser-Lys(Fam)- NH2 was processed as well but with less efficiency. A more selective substrate for ADAM9 was found based on the betacellulin cleavage site. However, the valine containing precursor TNF-alpha based substrate was used to measure IC50 values of metalloproteinase inhibitors against ADAM9 since it was processed most efficiently. The tightest binding inhibitor was the Wyeth Aerst compound, TMI-1, with an IC50 of 2.1 ± 0.3 nM. In addition, GI254023, previously identified as a selective inhibitor of ADAM10, also inhibited ADAM9 with an IC50 of 280 ± 110 nM. These results demonstrate that sensitive substrates for ADAM9 can be developed that are useful in high throughput screening assays for ADAM9.
Keywords: ADAM8, ADAM9, ADAM10, ADAM12, ADAM17, TACE, fluorescent, substrate, inhibitor, TMI-1, GI254023, GM6001, disintegrin, metalloproteinase, FRET, CD23, TGF-alpha
Combinatorial Chemistry & High Throughput Screening
Title: Fluorescent Substrates Useful as High Throughput Screening Tools for ADAM9
Volume: 13 Issue: 4
Author(s): Marcia L. Moss, Fred H. Rasmussen, Raphael Nudelman, Peter J. Dempsey and Jason Williams
Affiliation:
Keywords: ADAM8, ADAM9, ADAM10, ADAM12, ADAM17, TACE, fluorescent, substrate, inhibitor, TMI-1, GI254023, GM6001, disintegrin, metalloproteinase, FRET, CD23, TGF-alpha
Abstract: Fluorescence resonance energy transfer substrates were designed and tested as substrates for ADAM9. The donor/quencher pair used were 5-carboxyfluorescein (Fam) and 4-(4-dimethyl-aminophenylazo)benzoyl (Dabcyl) since they have been well studied sensitive fluorescent probes. The peptides based on precursor TNF-alpha, Dabcyl-Ser-Pro- Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser-Lys(Fam)-NH2 and Dabcyl-Leu-Ala-Gln-Ala-HomoPhe-Arg-Ser-Lys(Fam)-NH2, and C-terminal TGF-alpha, Dabcyl-Glu-His-Ala-Asp-Leu-Leu-Ala-Val-Val-Ala-Ala-Lys(Fam)-NH2 cleavage sites were effectively processed by ADAM9 with turnover numbers of 100 ± 20 x 10-2 min-1, 20 ± 10 x 10-2 min-1, and 10 ± 3 x 10-2 min-1. In addition, a peptide based on the 33kDa cleavage site of the low affinity receptor for IgE, CD23, Dabcyl-Leu- Arg-Ala-Glu-Gln-Gln-Arg-Leu-Lys-Ser-Lys(Fam)- NH2 was processed as well but with less efficiency. A more selective substrate for ADAM9 was found based on the betacellulin cleavage site. However, the valine containing precursor TNF-alpha based substrate was used to measure IC50 values of metalloproteinase inhibitors against ADAM9 since it was processed most efficiently. The tightest binding inhibitor was the Wyeth Aerst compound, TMI-1, with an IC50 of 2.1 ± 0.3 nM. In addition, GI254023, previously identified as a selective inhibitor of ADAM10, also inhibited ADAM9 with an IC50 of 280 ± 110 nM. These results demonstrate that sensitive substrates for ADAM9 can be developed that are useful in high throughput screening assays for ADAM9.
Export Options
About this article
Cite this article as:
L. Moss Marcia, H. Rasmussen Fred, Nudelman Raphael, J. Dempsey Peter and Williams Jason, Fluorescent Substrates Useful as High Throughput Screening Tools for ADAM9, Combinatorial Chemistry & High Throughput Screening 2010; 13 (4) . https://dx.doi.org/10.2174/138620710791054259
DOI https://dx.doi.org/10.2174/138620710791054259 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
Call for Papers in Thematic Issues
Artificial Intelligence Methods for Biomedical, Biochemical and Bioinformatics Problems
Recently, a large number of technologies based on artificial intelligence have been developed and applied to solve a diverse range of problems in the areas of biomedical, biochemical and bioinformatics problems. By utilizing powerful computing resources and massive amounts of data, methods based on artificial intelligence can significantly improve the ...read more
Emerging trends in diseases mechanisms, noble drug targets and therapeutic strategies: focus on immunological and inflammatory disorders
Recently infectious and inflammatory diseases have been a key concern worldwide due to tremendous morbidity and mortality world Wide. Recent, nCOVID-9 pandemic is a good example for the emerging infectious disease outbreak. The world is facing many emerging and re-emerging diseases out breaks at present however, there is huge lack ...read more
Exploring Spectral Graph Theory in Combinatorial Chemistry
Scope of the Thematic Issue: Combinatorial chemistry involves the synthesis and analysis of a large number of diverse compounds simultaneously. Traditional methods rely on brute force experimentation, which can be time-consuming and resource-intensive. Spectral Graph Theory, a branch of mathematics dealing with the properties of graphs in relation to the ...read more
Integrating Network Pharmacology and Traditional Medicine: A New Perspective in Drug Mechanism Research
Network pharmacology is a network construction and network topology analysis strategy that combines pharmacology and pharmacodynamics. In recent years, network pharmacology has emerged as a powerful tool that can be integrated with pharmacology. Natural products commonly function in multicomponent, multitarget, and multipathway systems. Some examples encompass Ayurveda, traditional Chinese medicines ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Combinatorial Application of Nucleic Acid-Based Agents Targeting Protein Kinases for Cancer Treatment
Current Pharmaceutical Design Pharmacological Effect of Berberine Chloride in Propyl Thiouracil Induced Thyroidal Dysfunction - A Time Bound Study in Female Rats
Recent Patents on Drug Delivery & Formulation Sentinel Lymph Node Mapping in Early Stage Endometrial Cancer Patients in Low-Resource Settings
Current Women`s Health Reviews A Novel Approach to Inhibit Heat Shock Response as Anticancer Strategy by Coumarine Compounds Containing Thiazole Skeleton
Anti-Cancer Agents in Medicinal Chemistry Role of Genetic Factors in the Pathogenesis of Radial Deficiencies in Humans
Current Genomics Galectins: Major Signaling Modulators Inside and Outside the Cell
Current Molecular Medicine Matrix Metalloproteinases
Current Medicinal Chemistry Anticancer α-Helical Peptides and Structure / Function Relationships Underpinning Their Interactions with Tumour Cell Membranes
Current Protein & Peptide Science Mechanisms of Resistance to Photodynamic Therapy
Current Medicinal Chemistry High Therapeutic Potential for Systemic Delivery of a Liposomeconjugated Herpes Simplex Virus
Current Cancer Drug Targets Biology and Therapeutic Applications of Peroxisome Proliferator- Activated Receptors
Current Topics in Medicinal Chemistry Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy
Recent Patents on Anti-Cancer Drug Discovery Management of Antineutrophil Cytoplasmic Antibody Associated Vasculitis
Current Immunology Reviews (Discontinued) PPAR- γ Agonist in Treatment of Diabetes: Cardiovascular Safety Considerations
Cardiovascular & Hematological Agents in Medicinal Chemistry Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Targeting the Lung: Preclinical and Comparative Evaluation of Anticancer Aerosols in Dogs with Naturally Occurring Cancers
Current Cancer Drug Targets Analysis of the Potential for HIV-1 Vpr as an Anti-Cancer Agent
Current HIV Research Oxidative Stress, Pro-Inflammatory Cytokines, and Antioxidants Regulate Expression Levels of MicroRNAs in Parkinson’s Disease
Current Aging Science Current State of ERG as Biomarker in Prostatic Adenocarcinoma
Current Cancer Drug Targets Putative Breast Tumor Suppressor TACC2 Suppresses the Aggressiveness of Breast Cancer Cells through a PLCγ Pathway
Current Signal Transduction Therapy